SlimBiome study update
RNS & Investor News
Placing
05 February 2016
OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing products to tackle obesity, high cholesterol and diabetes is pleased to announce that it has raised £1,000,000 (before expenses) via a placing of 1,282,051 new ordinary shares ("Placing Shares") at a price of 78 pence per share (the "Placing").
The Placing Shares have been issued to funds managed by Seneca Partners Limited ("Seneca"), a wealth manager and existing institutional investor in OptiBiotix. Following the Placing, Seneca's beneficial shareholding in the Company is 5,537,051 ordinary shares, representing 7.13 per cent. of the Company's issued share capital.
Stephen O'Hara, CEO of OptiBiotix, said: "We are delighted that Seneca, as a major shareholder and respected wealth manager, have increased their stake in OptiBiotix. The funds will be used to further accelerate our development programmes to capitalise on the growing number of opportunities arising in the rapidly evolving microbiome space and build shareholder value."
Application will be made to the London Stock Exchange to admit the Placing Shares to trading on AIM. Admission of the Placing Shares is expected to occur on or around 11 February 2016. The Placing Shares will rank pari passu with the Company's existing ordinary shares.
For the purpose of the Disclosure and Transparency Rules, following the issue of the Placing Shares, the enlarged issued share capital of the Company will comprise 77,633,976 ordinary shares of 2p each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.
For further information:
OptiBiotix Health Plc Stephen O'Hara, Chief Executive |
www.optibiotix.com Contact via Walbrook below |
Cairn Financial Advisers LLP Liam Murray / Avi Robinson |
Tel: 020 7148 7900 |
Hybridan LLP (Joint Broker) Claire Louise Noyce |
Tel: 0203 764 2341 |
Peterhouse Corporate Finance Ltd (Joint Broker) Lucy Williams / Duncan Vasey |
Tel: 020 7469 0936 |
Walbrook PR Ltd Anna Dunphy Mike Wort |
Tel: 020 7933 8780 or [email protected] Mob: 07876 741 001 Mob: 07900 608 002 |
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
Latest Video
ProBiotix Health anticipating "big commercial opportunities" during 2023
Group CEO Stephen O’Hara and CEO Steen Anderson | 04 January 2023
www.proactiveinvestors.co.uk
Latest Podcast
Stephen OHara interview with Investors Champion
Stephen O'Hara | 04 Jul 2019
www.investorschampion.com